Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.

Abstract

Eribulin is a structurally simplified, synthetic macrocyclic ketone analog of halichondrin B, which is a natural, polyether macrolide derived from marine sponges. Eribulin exerts its cytotoxicity by its unique microtubule dynamics inhibitory action. Eribulin was approved in 2010 by the US FDA as a third-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. In 2016, it was approved for treatment of metastatic liposarcoma for patients who have progressed with anthracycline treatment. In this article, we review the pharmacokinetics, mechanism of action of eribulin with focus on preclinical and clinical data in sarcoma and also the role of miRNAs in soft tissue sarcomas.

• Authors: Mahesh Seetharam, Kantha R Kolla, Sant P Chawla
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 16 Pg. 1531-1545 (Jul 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29411654 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Furans
• Ketones
• eribulin

Topics

• Animals
• Antineoplastic Agents (pharmacokinetics, therapeutic use)
• Biomarkers, Tumor (genetics)
• Clinical Trials as Topic
• Furans (pharmacokinetics, therapeutic use)
• Humans
• Immunotherapy (methods)
• Ketones (pharmacokinetics, therapeutic use)
• Sarcoma (drug therapy, mortality, pathology)